What is Nabla?
Nabla operates at the intersection of artificial intelligence and clinical practice, providing a sophisticated toolset designed to alleviate the documentation fatigue currently plaguing the medical profession. By leveraging advanced natural language processing, the platform generates accurate, structured clinical notes directly from patient consultations, allowing practitioners to focus on patient care rather than administrative data entry. Headquartered in Paris, the company has established itself as a pivotal player in the digital health sector, addressing the systemic need for workflow optimization in hospitals and private practices alike. Its technology is engineered to integrate seamlessly into existing electronic health record systems, ensuring that the transition to AI-assisted documentation is both intuitive and scalable for large-scale medical organizations.
How much funding has Nabla raised?
Nabla has raised a total of $112.8M across 3 funding rounds:
Series A
$18.8M
Series B
$24M
Series C
$70M
Series A (2020): $18.8M, investors not publicly disclosed
Series B (2024): $24M led by Cathay Innovation and Zebox Ventures
Series C (2025): $70M supported by HV Capital, Cathay Innovation, Highland Europe, and BC Mgmt
Key Investors in Nabla
HV Capital
A prominent venture firm based in Germany that specializes in supporting early-stage and growth-stage businesses with a focus on long-term value creation.
Cathay Innovation
A global venture capital firm that connects startups to a worldwide ecosystem, focusing on multi-stage investments in sectors like healthcare and technology.
Highland Europe
A growth-stage investment firm that provides capital to product-led software companies, emphasizing founder-centric values and strong market momentum.
What's next for Nabla?
With the successful closure of this major strategic investment, Nabla is well-positioned to scale its operations and deepen its technological moat. The company's strategic roadmap likely involves expanding its footprint in the European and North American markets, where the demand for AI-driven clinical efficiency is at an all-time high. Furthermore, the influx of capital will likely support the development of advanced features, such as predictive analytics and deeper integration with diagnostic tools, to provide a more holistic support system for clinicians. As the healthcare industry continues to grapple with staffing shortages and burnout, Nabla's ability to streamline documentation processes positions it as a vital partner for health systems aiming to improve operational throughput and clinician retention. The firm's focus will remain on maintaining high standards of data privacy and clinical accuracy as it transitions into its next phase of enterprise-wide adoption.
See full Nabla company page
